LENSAR Valuation Multiples

LENSAR Overview

About LENSAR

LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.

Founded

2004

HQ

Employees

140

Website

lensar.com

Sectors

Medical DevicesBioTechLongevity

Financials (LTM)

Revenue: $51M

EBITDA: ($875K)

EV

$56M

Valuation Multiples

Multiples.vc

Start free trial

LENSAR Financials

LENSAR reported last 12-month revenue of $51M and negative EBITDA of ($875K).

In the same LTM period, LENSAR generated $19M in gross profit, ($875K) in EBITDA losses, and had net loss of ($25M).

LENSAR P&L

In the most recent fiscal year, LENSAR reported revenue of $58M and EBITDA of $200K.

LENSAR expects next 12-month revenue of XXX and NTM EBITDA of XXX

LENSAR Stock Performance

LENSAR has current market cap of $72M, and enterprise value of $56M.

LENSAR's stock price is $5.93.

LENSAR Valuation Multiples

LENSAR trades at 1.1x EV/Revenue multiple, and (64.5x) EV/EBITDA.

LENSAR Financial Valuation Multiples

As of April 20, 2026, LENSAR has market cap of $72M and EV of $56M.

Equity research analysts estimate LENSAR's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

LENSAR has a P/E ratio of (2.9x).

LENSAR Margins & Growth Rates

LENSAR's revenue in the last 12 month grew by 31%.

LENSAR's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.

LENSAR's rule of 40 is 3% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

LENSAR's rule of X is 14% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

LENSAR Public Comps

See public comps and valuation multiples for other Medical Devices comps.

LENSAR M&A Activity

LENSAR acquired XXX companies to date.

Last acquisition by LENSAR was on XXXXXXXX, XXXXX. LENSAR acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

LENSAR Investment Activity

LENSAR invested in XXX companies to date.

LENSAR made its latest investment on XXXXXXXX, XXXXX. LENSAR invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).